EVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evotec SE is not a strong buy for a beginner, long-term investor at this time. While there are some positive developments, such as the collaboration with the US government, the company's financial performance shows declining revenue and negative margins. Additionally, the technical indicators and lack of strong trading signals suggest no immediate entry point. It is better to hold off for now and monitor the stock for better opportunities.
The MACD is positive and expanding, which is a bullish sign, but the RSI is neutral at 43.482, showing no clear momentum. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot point of 2.433 with resistance at 2.533 and support at 2.333. Overall, the technical indicators suggest a weak or neutral trend.
Evotec's biologics unit, Just - Evotec Biologics, has been selected by the US government for collaboration, which could enhance its influence in the biopharmaceutical sector.
Analysts have also lowered price targets recently.
In Q3 2025, revenue dropped by -5.70% YoY to $191.55M. Net income improved slightly but remains negative at -$50.36M (+15.65% YoY). EPS increased to -0.28 (+12.00% YoY), but gross margin dropped significantly to -0.04 (-100.40% YoY).
Analyst ratings are mixed. Deutsche Bank recently lowered its price target to EUR 4.50 and maintained a Hold rating. Berenberg initiated coverage with a Buy rating and a EUR 10 price target, citing the company's strong position in drug discovery and favorable market trends. However, no consistent upward momentum in analyst sentiment is observed.
